Skip to content

Study on the stability assessment Model of intracranial small aneurysm based on artificial intelligence: a prospective, multicentre, controlled clinical study using the clinical characteristics of aneurysm patients and morphological parameters of aneurysms

Study on the stability assessment Model of intracranial small aneurysm based on artificial intelligence: a prospective, multicentre, controlled clinical study using the clinical characteristics of aneurysm patients and morphological parameters of aneurysms

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041085
Enrollment
Unknown
Registered
2020-12-17
Start date
2020-12-14
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysms with the longest diameter less than 5 mm

Interventions

Index test:The&#32
assessment&#32
Model&#32
of&#32
based&#32
on&#32
artificial&#32

Sponsors

The First Affiliated Hospital of Jinan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age ranges from 18 to 80 years old (including 18 and 80 years old), regardless of gender; 2. No previous history of aneurysmal subarachnoid hemorrhage; 3. No previous sudden severe headache, oculomotor nerve paralysis, stiff neck, photophobia or transient loss of consciousness,a history of sudden seizures; 4. CTA, MRA or DSA within 1 month were diagnosed as intracranial cystic small aneurysm (<5mm); 5. Patients with the small aneurysms promised to be followed up; 6. The patient agreed to participate in the trial and voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Poor image quality of CTA, MRA or DSA, such as motion artifacts and metal artifacts and so on; 2. Target aneurysms are vacuolar aneurysms, pseudoaneurysms, infectious aneurysms or aneurysms associated with arteriovenous malformations and moyamoya disease; 3. The investigator considers that the patient is not suitable to participate in the clinical trial; 4. Fail to cooperate with subsequent enrollment and follow-up.

Design outcomes

Primary

MeasureTime frame
rupture of aneurysms;SEN, SPE, ACC, AUC of ROC, PV+, PV-;

Countries

China

Contacts

Public ContactWen Jun

The First Affiliated Hospital of Jinan University

wenjun20150766@163.com+86 15989190143

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026